John Bishop - 28 Feb 2022 Form 4 Insider Report for Forma Therapeutics Holdings, Inc. (FMTX)

Role: SVP, Chief Technology Officer
Signature: /s/ Jeannette Potts, as Attorney-in-Fact
Issuer symbol: FMTX
Transactions as of: 28 Feb 2022
Transactions value $: $0
Form type: 4
Filing time: 02 Mar 2022, 16:14:30 UTC
Previous filing: 15 Jun 2021
Next filing: 14 Oct 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	FMTX	Common Stock	Award	$0	+25,950	+1.18%	$0	47,950	28 Feb 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	FMTX	Stock Option (Right to Buy)	Award	$0	+38,930		$0	38,930	28 Feb 2022	Common Stock	38,930	$9.86	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares represented restricted stock units and will be settled into common stock upon vesting. Each restricted stock unit would be converted into one share of FMTX common stock.
F2	25% of the shares subject to the stock option shall vest on February 28, 2023, and the remainder of the shares vest in equal monthly installments for a period of 36 months thereafter.